clinical benefit rate
Showing 9951 - 9975 of >10,000
Nontuberculous Mycobacterial Lung Disease Trial in Shanghai (New regimen(BdqCfzLzd+XY))
Not yet recruiting
- Nontuberculous Mycobacterial Lung Disease
- New regimen(BdqCfzLzd+XY)
-
Shanghai, ChinaShanghai Pulmonary Hospital
Aug 8, 2022
Confirmed Diagnosis of Hepatocellular Carcinoma, Patients Who Are Scheduled to Undergo Transarterial Chemobolization, Systemic
Recruiting
- Confirmed Diagnosis of Hepatocellular Carcinoma
- +2 more
- Fibroscan
-
Hong Kong, Hong KongDepartment of Clinical Oncology, Prince of Wales Hospital
Feb 9, 2022
Immature Teeth, Periapical Lesion Trial in Damascus (Bioceramic Putty Apical Plugs, Single Cone Gutta-percha with Bioceramic
Recruiting
- Immature Teeth
- Periapical Lesion
- Bioceramic Putty Apical Plugs
- +2 more
-
Damascus, Syrian Arab RepublicDamascus University
Oct 31, 2023
Wound Infection, Fractures, Open, Surgical Site Infection Trial in Lexington (Tobramycin Injection)
Recruiting
- Wound Infection
- +2 more
- Tobramycin Injection
-
Lexington, KentuckyUniversity of Kentucky
Jan 28, 2022
Tissue Injury, Surgery, Absorption; Disorder Trial in Istanbul (StO2, O3)
Recruiting
- Tissue Injury
- +2 more
- StO2
- O3
-
Istanbul, TurkeyMarmara University
Dec 16, 2021
Intrahepatic Cholangiocarcinoma, Transarterial Chemoembolization, Apatinib Trial in Chengdu (DEB-TACE combined with apatinib and
Not yet recruiting
- Intrahepatic Cholangiocarcinoma
- +3 more
- DEB-TACE combined with apatinib and PD-1 antibody
-
Chengdu, Sichuan, ChinaSichuan Cancer Hospital and Research Institute
Apr 4, 2021
End Stage Renal Disease Trial (Percutaneous translumbar and transhepatic permcath)
Not yet recruiting
- End Stage Renal Disease
- Percutaneous translumbar and transhepatic permcath
- (no location specified)
Dec 17, 2022
Life Quality, Hospital Mortality Trial (high protein, rehabilitation, standard protein)
Not yet recruiting
- Life Quality
- Hospital Mortality
- high protein
- +2 more
- (no location specified)
Mar 24, 2023
Patients With Pulmonary Hypertension
Not yet recruiting
- Pulmonary Hypertension
-
San Francisco, CaliforniaPower Life Sciences
Jun 23, 2023
Participation Patterns Among Recurrent Ovarian Cancer Patients
Not yet recruiting
- Recurrent Ovarian Cancer
-
San Francisco, CaliforniaPower Life Sciences
Sep 30, 2023
T-Cell Large Granular Lymphocyte Leukemia Trial in Columbus (Ruxolitinib)
Not yet recruiting
- T-Cell Large Granular Lymphocyte Leukemia
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Oct 20, 2022
IBD, Crohn Disease, Ulcerative Colitis Trial (Remote monitoring)
Recruiting
- Inflammatory Bowel Diseases
- +2 more
- Remote monitoring
-
Baltimore, Maryland
- +4 more
Jan 11, 2023
Gestational Diabetes, Pregestational Diabetes Trial in Houston (Usual Care, Permissive intrapartum glucose control)
Recruiting
- Gestational Diabetes
- Pregestational Diabetes
- Usual Care
- Permissive intrapartum glucose control
-
Houston, TexasThe University of Texas Health Science Center at Houston
Oct 7, 2022
Gastrointestinal Cancer Trial in Charlotte (Oncology Nurse Navigation)
Recruiting
- Gastrointestinal Cancer
- Oncology Nurse Navigation
-
Charlotte, North CarolinaLevine Cancer Institute
Apr 12, 2022
Primary Hepatocellular Carcinoma Trial (Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)), camrelizumab for
Not yet recruiting
- Primary Hepatocellular Carcinoma
- Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))
- camrelizumab for Injection
- (no location specified)
Nov 13, 2023
Leukemia Trial in Montpellier (Dressing change)
Not yet recruiting
- Leukemia
- Dressing change
-
Montpellier, FranceCHU de Montpellier Hôpital St-Eloi
Mar 20, 2023
Therapeutic Alliance, Empathy Trial in Tilburg (Cultural Formulation Interview)
Not yet recruiting
- Therapeutic Alliance
- Empathy
- Cultural Formulation Interview
-
Tilburg, Brabant, NetherlandsOnderzoek Consortium Samen Sterker
Mar 30, 2023
Registry Study in MSI/dMMR Solid Tumors
Not yet recruiting
- DMMR Cancer
- +2 more
- (no location specified)
Aug 21, 2023
Nausea and Vomiting Trial in Sichuan (Heptaflurane combined Cyclophenol, Heptaflurane, Cyclophenol)
Enrolling by invitation
- Nausea and Vomiting
- Heptaflurane combined Cyclophenol
- +2 more
-
Sichuan, ChinaSichuan Provincial People's Hospital
Apr 19, 2023
Linguistic Predictors of Outcomes in Psychosis
Active, not recruiting
- Schizophrenia and Related Disorders
- There is no intervention
-
Glen Oaks, New YorkZucker Hillside Hospital
Oct 29, 2022
Colorectal Cancer, Adenoma, Intestinal Polyps Trial in Nîmes (GI GENIUS™ artificial intelligence system, ENDOCUFF VISION®
Not yet recruiting
- Colorectal Cancer
- +2 more
- GI GENIUS™ artificial intelligence system
- ENDOCUFF VISION® endoscopic cap
-
Nîmes, FranceCHU de Nîmes
Oct 21, 2022
HIV-1-infection, Subtype b Trial (Decitabine cycle 1, Romidepsin cycle 1, Decitabine cycle 2)
Recruiting
- HIV-1-infection, Subtype b
- Decitabine cycle 1
- +7 more
-
Bruxelles, Belgium
- +2 more
Jan 30, 2023
MDD Trial in Worldwide (Vortioxetine, Desvenlafaxine)
Completed
- Major Depressive Disorder
-
Banfield, Buenos Aires, Argentina
- +79 more
Feb 11, 2022
Speech Intelligibility, Aging Trial in College Park (Auditory-cognitive training paradigm, Auditory training paradigm, Active
Recruiting
- Speech Intelligibility
- Aging
- Auditory-cognitive training paradigm
- +2 more
-
College Park, Maryland
- +1 more
Mar 23, 2022
Seasonal Factors and COVID 19
Completed
- COVID-19 Pandemic
- Polymerase chain reaction
-
İzmir, TurkeyIKCU, Atatürk Eğitim ve Araştırma Hastanesi, Acil Tıp
Mar 1, 2022